Harrogate school opens garden in memory of former pupil
A primary school has opened a memorial garden in honour of a seven-year-old former pupil who passed away after a battle with leukaemia. The garden at Brackenfield School in Harrogate was opened this week in memory of Arabella Sturgeon, who died in February from complications related to a stem cell transplant. Arabella's mum, Natalie Sadler, said she wanted the garden to be a place where her daughter's peers and teachers could "come and sit and be quiet or do some crafting or just remember Arabella". She said: "This school's been such a huge support for us. It's so wonderful that [Arabella's] legacy is continuing and carrying on."
Ms Sadler described her daughter as someone who "would light up any room she went into" and "didn't care what anybody thought". She added: "She would dance like no-one was watching, she was there for her friends, she was kind."She was unapologetically Arabella."Headteacher at Brackenfield, Joe Masterson, said the school community took part in a ceremony to open the garden and celebrate Arabella's life, which saw students sing songs and read poems. Speaking at the ceremony on Thursday, he said: "Although today was tinged with sadness there was also a lot of happiness."
Ms Sadler has also headed up a fundraising campaign for charity Cure Leukaemia since Arabella's death, having already raised more than £13,000. Bhupinder Dhillon from the charity, who attended the garden opening, said the funding would go towards world-first trials targeted at blood cancer in children. Gemma Hathaway, also from Cure Leukaemia, said: "Blood cancer actually isn't rare in children, four children a day are diagnosed with blood cancer."She said the funding would also go towards the launch of the charity's ATICUS (Accelerating Trials in Children Undergoing Stem Cell Transplant) Network in Leeds. The network connects children with blood cancer across the UK with leading children's hospitals to "revolutionise clinical trial access" and prevent future deaths from the disease. Ms Hathaway said: "While it's an absolute honour to be here, we don't want to be here - it's another life lost far, far, far too young."
Listen to highlights from North Yorkshire on BBC Sounds, catch up with the latest episode of Look North.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
13-06-2025
- Scottish Sun
Our brave Jasper is slowly losing the ability to walk – a drug could change that but the NHS cruelly won't fund it
Find out everything you need to know about Jasper's condition below LIVING NIGHTMARE Our brave Jasper is slowly losing the ability to walk – a drug could change that but the NHS cruelly won't fund it Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) THE family of a 10-year-old boy who's losing the ability to walk have described the 'nightmare' battle they face with the NHS to access a free drug for help. Rosie and Pete Day from Horsham, West Sussex have been fighting for the drug givinostat for their son Jasper who has Duchenne muscular dystrophy (DMD). Sign up for Scottish Sun newsletter Sign up 4 Jasper and his twin sister both have Duchenne muscular dystrophy - but Arabella is a carrier while Jasper is most affected Credit: PA 4 The Day family are fighting for Jasper to get givinostat, which can slow progression of the condition Credit: PA Duchenne is a genetic muscle wasting condition that causes progressive muscle weakness. In the UK, an estimated 2,500 people are living with the condition The Day family have twins Jasper and Arabella, and two older daughters. Both Jasper and his twin sister Arabella have Duchenne, with Arabella a carrier and Jasper the most affected - as the condition mostly affects boys. Read more on muscle conditions BEHIND BARS Woman left battling fatal 'muscle death' triggered by first ever spin class Givinostat, developed by ITF Pharma UK, can slow progress of Duchenne - keeping children on their feet for longer - and is being offered for free by a drug firm while it goes through the process of NHS approval. Only some NHS trusts across the UK, and few in England, are giving out the drug despite it being part of an early access programme since November. Families are now facing a "cruel" postcode lottery over who gets the medicine and are in a race against time, according to the charity Duchenne UK. Some NHS trusts are refusing to supply the drug while others delay it by drawing up lists of who they think should get it first. NHS trusts say they need to pay for monitoring the drug - around £1,900 per year per patient - out of their own budget. Rosie said: "We try and live in the moment and, in this moment, there's an opportunity to make a massive change to Jasper. Toddler, 3, left fighting for life after 'going off his food' - as killer cocktail of common viruses attacked his heart "We're not going to cure it, but this drug gives him the best chance of having the early life that he wants to have and what every parent wants to give their child. "It's so close - and yet we're stuck. "We're stuck in this process where there's something in reaching distance that could make a huge difference to keep him walking, keep him active, keep him with his siblings in the garden, keep him walking up the stairs, all of those things, and it just feels that we can't quite get there. "We're on the finishing line to get something that will make a difference and we can't quite get there because of the system we're in. "The drug is not going to cure it, but it will give him the childhood you would wish to give your child - to keep them playing football, coming on dog walks, being able to walk up the stairs, playing the French horn, all of those things that you dream your child is going to get to do.' She added: "It feels like a nightmare, because you know that the doctors want to give it, but when it comes to getting the drug in his mouth and seeing what it would do, we're stuck. "It's a lottery, basically, depending on where you are in the country ... and within NHS trusts themselves." 'When will I get the drug, mummy?' Jasper is under the care of the Evelina London Children's Hospital, which is only now starting to contact patients and is drawing up a priority list for who gets the drug first. "Every day that passes by is a day that we can see Jasper decline and see him struggling with his muscles," Mrs Day said. "Two weeks ago, he asked me, 'When will I get the drug, mummy?' "We're stuck in a situation over who's going to make those decisions regarding who gets the drug - of whether Jasper gets it or another boy. "For every boy it's heartbreaking, because someone ultimately is not going to get the drug at that moment based on the current criteria." She continued: "If Jasper stops walking, we're not going to get that back. We're stuck in a situation over who's going to make those decisions regarding who gets the drug - of whether Jasper gets it or another boy Rosie Day "Every day matters. Six months ago, Jasper could walk up and down the stairs easily. He can't do that now and Pete has to push him up the stairs every night. "Yet we can't give him something that is as simple as two spoons full of medicine and a blood test, and a little bit of maybe resource looking at the blood test results - that is what is standing in our way." Rosie said it was unclear how the Evelina is "going to make a fair choice" because knowing who will lose mobility is not an exact science. And she said the process is "hugely subjective" because there is no linear decline in the condition and the decisions made by NHS trusts could end up being "completely wrong". According to Duchene UK, boys whose condition is getting worse risk falling off the list entirely while waiting for the drug. Around 500 boys in the UK are eligible for givinostat, which can be taken at home like Calpol, with hospitals then doing follow-up blood tests of around eight in the first year, followed by twice a year thereafter. 4 Jasper is under the care of the Evelina London Children's Hospital, but it's unclear whether they'll give him the drug Credit: PA 4 The family say the NHS needs to urgently make the drug available to both ambulant (walking) and non-ambulant boys Credit: PA Children may also need an ECG, though these are already part of routine Duchenne monitoring. Emily Reuben and Alex Johnson, founders of Duchenne UK, said: "As time ticks by, more boys are losing out on their chance to access givinostat. "This is a simple treatment, which can be easily managed at home, and requires uncomplicated blood tests to monitor. It's free to the NHS and could offer real hope for patients and their families. "The delays are cruel and the postcode lottery is unjustifiable. We are calling on the NHS to urgently make this available to both ambulant (walking) and non-ambulant boys." To date, all health boards in Scotland are rolling out the drug, alongside those in Swansea and Cardiff. Leicester Royal Infirmary was the first trust in England to give the drug, but the Evelina has not yet, and neither have trusts in Manchester, Liverpool and Newcastle. Great Ormond Street Hospital is working to supply the drug. A spokesman for the Evelina said: "We have begun contacting families of all existing Evelina London patients who may be eligible for givinostat and are working to set up appointments in the next few months. "Our clinical team are working through our patient lists and are currently prioritising children who need the treatment most urgently, or are at a higher risk of losing movement (ambulation) soon." An NHS spokesman said: "The first National Institute for Health and Care Excellence (Nice) committee meeting to consider this treatment is scheduled to be held in July 2025, and if manufacturer ITF Pharma can offer a cost-effective price to enable Nice to recommend its use, the NHS will be ready to work with the company to explore fast-tracking access for patients. "NHS England has published guidance on manufacturer-led early access schemes, which require trusts to cover substantial costs and find additional clinical resources to administer new treatments, and we understand a number of trusts across the country are preparing to offer givinostat via such a scheme." Parents have met with Health Secretary Wes Streeting to try and speed up access.
ITV News
13-06-2025
- ITV News
Horsham parents whose sons are losing ability to walk face ‘nightmare' battle with NHS
Parents whose sons are losing the ability to walk have described the 'nightmare' battle they face with the NHS to access a free drug. The medicine givinostat can slow progress of Duchenne muscular dystrophy – keeping children on their feet for longer – and is being offered for free by a drug firm while it goes through the process of NHS approval. However, only some NHS trusts across the UK, and few in England, are giving the drug despite it being part of an early access programme since November. Families are now facing a 'cruel' postcode lottery over who gets the medicine and are in a race against time, according to the charity Duchenne UK. Some NHS trusts are refusing to supply the drug while others delay it by drawing up lists of who they think should get it first. NHS trusts say they need to pay for monitoring the drug – around £1,900 per year per patient – out of their own budget. In desperation, parents have met with Health Secretary Wes Streeting to try and speed up access. According to the Government, it is up to individual NHS trusts to decide whether to provide the drug. Duchenne UK is supporting families in their fight for givinostat, including Rosie and Pete Day, an investment manager, and their 10-year-old son Jasper, from Horsham, West Sussex. The Day family have twins Jasper and Arabella, aged 10, and two older daughters. Both Jasper and Arabella have Duchenne, with Arabella a carrier of the genetic disorder and Jasper the most affected, as the condition mostly affects boys. The drug, developed by ITF Pharma UK, is only being given under the early access programme to children who are still able to walk. Mrs Day told the PA news agency: 'We try and live in the moment and, in this moment, there's an opportunity to make a massive change to Jasper. 'We're not going to cure it, but this drug gives him the best chance of having the early life that he wants to have and what every parent wants to give their child. 'It's so close – and yet we're stuck. 'We're stuck in this process where there's something in reaching distance that could make a huge difference to keep him walking, keep him active, keep him with his siblings in the garden, keep him walking up the stairs, all of those things, and it just feels that we can't quite get there. 'We're on the finishing line to get something that will make a difference and we can't quite get there because of the system we're in. 'The drug is not going to cure it, but it will give him the childhood you would wish to give your child – to keep them playing football, coming on dog walks, being able to walk up the stairs, playing the French horn, all of those things that you dream your child is going to get to do. 'We can't give it because it we're stuck, even though it's free and it's there – we can't give it. 'It feels like a nightmare, because you know that the doctors want to give it, but when it comes to getting the drug in his mouth and seeing what it would do, we're stuck. 'It's a lottery, basically, depending on where you are in the country … and within NHS trusts themselves.' Jasper is under the care of the Evelina London Children's Hospital, which is only now starting to contact patients and is drawing up a priority list for who gets the drug first. 'Every day that passes by is a day that we can see Jasper decline and see him struggling with his muscles,' Mrs Day said. 'Two weeks ago, he asked me, 'When will I get the drug, mummy?' 'We're stuck in a situation over who's going to make those decisions regarding who gets the drug – of whether Jasper gets it or another boy. 'For every boy it's heartbreaking, because someone ultimately is not going to get the drug at that moment based on the current criteria.' She added: 'If Jasper stops walking, we're not going to get that back. 'Every day matters. Six months ago, Jasper could walk up and down the stairs easily. He can't do that now and Pete has to push him up the stairs every night. 'Yet we can't give him something that is as simple as two spoons full of medicine and a blood test, and a little bit of maybe resource looking at the blood test results – that is what is standing in our way.' Mrs Day said it was unclear how the Evelina is 'going to make a fair choice' because knowing who will lose mobility is not an exact science. Mr Day said the process is 'hugely subjective' because there is no linear decline in the condition and the decisions made by NHS trusts could end up being 'completely wrong'. According to Duchene UK, boys whose condition is getting worse risk falling off the list entirely while waiting for the drug. Around 500 boys in the UK are eligible for givinostat, which can be taken at home like Calpol, with hospitals then doing follow-up blood tests of around eight in the first year, followed by twice a year thereafter. Children may also need an ECG, though these are already part of routine Duchenne monitoring. Emily Reuben and Alex Johnson, founders of Duchenne UK, said: 'As time ticks by, more boys are losing out on their chance to access givinostat. 'This is a simple treatment, which can be easily managed at home, and requires uncomplicated blood tests to monitor. It's free to the NHS and could offer real hope for patients and their families. 'The delays are cruel and the postcode lottery is unjustifiable. We are calling on the NHS to urgently make this available to both ambulant (walking) and non-ambulant boys.' To date, all health boards in Scotland are rolling out the drug, alongside those in Swansea and Cardiff. Leicester Royal Infirmary was the first trust in England to give the drug, but the Evelina has not yet, and neither have trusts in Manchester, Liverpool and Newcastle. Great Ormond Street Hospital is working to supply the drug. A spokesman for the Evelina said: 'We have begun contacting families of all existing Evelina London patients who may be eligible for givinostat and are working to set up appointments in the next few months. 'Our clinical team are working through our patient lists and are currently prioritising children who need the treatment most urgently, or are at a higher risk of losing movement (ambulation) soon.' An NHS spokesman said: 'The first National Institute for Health and Care Excellence (Nice) committee meeting to consider this treatment is scheduled to be held in July 2025, and if manufacturer ITF Pharma can offer a cost-effective price to enable Nice to recommend its use, the NHS will be ready to work with the company to explore fast-tracking access for patients. 'NHS England has published guidance on manufacturer-led early access schemes, which require trusts to cover substantial costs and find additional clinical resources to administer new treatments, and we understand a number of trusts across the country are preparing to offer givinostat via such a scheme.'
Daily Mirror
13-06-2025
- Daily Mirror
Mum of boys losing ability to walk face 'nightmare' battle for free NHS drug
Givinostat can slow the progression of Duchenne muscular dystrophy and is being offered for free by a drug firm while it goes through the process of NHS approval Parents are locked in a "nightmare" struggle with the NHS to secure a vital drug that could help their sons walk for longer, as they face a "cruel" postcode lottery for treatment. Twins, Jasper and Arabella, both aged 10, are battling Duchenne, with Jasper severely affected as the disorder predominantly strikes boys. While Arabella is a carrier of Duchenne, Jasper's condition is more advanced due to the nature of the genetic disorder. The drug givinostat has shown promise in slowing the progression of Duchenne muscular dystrophy and is being offered at no cost by a pharmaceutical company while awaiting NHS approval. Despite being part of an early access scheme since November, only a handful of NHS trusts across the UK, with even fewer in England, are distributing the medication. Charity Duchenne UK has highlighted the urgent race against time families are enduring to obtain givinostat, with some NHS trusts denying access or causing delays by creating priority lists. NHS trusts have cited the cost of monitoring the drug, approximately £1,900 annually per patient, which must come from their budgets, as a reason for not providing it. In a bid to hasten access, desperate parents have approached Health Secretary Wes Streeting. The Government maintains that the decision to supply the drug rests with individual NHS trusts. Duchenne UK is backing several families in their battle, including Rosie and Pete Day, an investment manager, and their 10 year old son Jasper from Horsham, West Sussex. ITF Pharma UK has developed a promising drug, but it's currently only available to ambulant children through an early access programme. Mrs Day shared her family's hopes and struggles: "We try and live in the moment and, in this moment, there's an opportunity to make a massive change to Jasper." She continued passionately, stating that while they can't find a cure, "We're not going to cure it, but this drug gives him the best chance of having the early life that he wants to have and what every parent wants to give their child." However, her voice took on a tone of desperation as she added, "It's so close – and yet we're stuck." With palpable frustration, she explained, "We're stuck in this process where there's something in reaching distance that could make a huge difference to keep him walking, keep him active, keep him with his siblings in the garden, keep him walking up the stairs, all of those things, and it just feels that we can't quite get there." Highlighting the potential impact of the drug, she revealed, "The drug is not going to cure it, but it will give him the childhood you would wish to give your child – to keep them playing football, coming on dog walks, being able to walk up the stairs, playing the French horn, all of those things that you dream your child is going to get to do." Her lament continued, "We can't give it because we're stuck, even though it's free and it's there – we can't give it. It feels like a nightmare, because you know that the doctors want to give it, but when it comes to getting the drug in his mouth and seeing what it would do, we're stuck. "It's a lottery, basically, depending on where you are in the country ... and within NHS trusts themselves. Every day that passes by is a day that we can see Jasper decline and see him struggling with his muscles. Two weeks ago, he asked me, 'When will I get the drug, mummy?'". "We're stuck in a situation over who's going to make those decisions regarding who gets the drug – of whether Jasper gets it or another boy. For every boy it's heartbreaking, because someone ultimately is not going to get the drug at that moment based on the current criteria." She added: "If Jasper stops walking, we're not going to get that back. Every day matters. Six months ago, Jasper could walk up and down the stairs easily. He can't do that now and Pete has to push him up the stairs every night. Yet we can't give him something that is as simple as two spoons full of medicine and a blood test, and a little bit of maybe resource looking at the blood test results – that is what is standing in our way." Mrs Day expressed her uncertainty about how the Evelina is "going to make a fair choice" as predicting who will lose mobility isn't an exact science. Mr Day described the process as "hugely subjective", stating that there's no linear decline in the condition and decisions made by NHS trusts could end up being "completely wrong". Emily Reuben and Alex Johnson, founders of Duchenne UK, stated: "As time ticks by, more boys are losing out on their chance to access givinostat. This is a simple treatment, which can be easily managed at home, and requires uncomplicated blood tests to monitor. It's free to the NHS and could offer real hope for patients and their families. The delays are cruel and the postcode lottery is unjustifiable. We are calling on the NHS to urgently make this available to both ambulant (walking) and non-ambulant boys." To date, all health boards in Scotland are rolling out the drug, alongside those in Swansea and Cardiff. Leicester Royal Infirmary has made history as the first hospital trust in England to administer a new drug, but other trusts including those in Manchester, Liverpool, and Newcastle, along with the Evelina, have yet to follow suit. Great Ormond Street Hospital is on track to provide the lifesaving medication. Speaking about the treatment's availability, an Evelina spokesperson revealed: "We have begun contacting families of all existing Evelina London patients who may be eligible for givinostat and are working to set up appointments in the next few months. Our clinical team are working through our patient lists and are currently prioritising children who need the treatment most urgently, or are at a higher risk of losing movement (ambulation) soon." From the NHS front, a representative shared: "The first National Institute for Health and Care Excellence (Nice) committee meeting to consider this treatment is scheduled to be held in July 2025, and if manufacturer ITF Pharma can offer a cost-effective price to enable Nice to recommend its use, the NHS will be ready to work with the company to explore fast-tracking access for patients." They continued, explaining the position on early access schemes: "NHS England has published guidance on manufacturer-led early access schemes, which require trusts to cover substantial costs and find additional clinical resources to administer new treatments, and we understand a number of trusts across the country are preparing to offer givinostat via such a scheme."
